Kairos Pharma Ltd: reports interim phase 2 efficacy data for ENV-105

What happened Kairos Pharma, Ltd. reported on Oct 6, 2026 that it issued a press release reporting interim efficacy data from its ongoing phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The company furnished the press release with the Current Report on Form 8-K.

Key details

• The press release was issued and furnished on Oct 6, 2026.
• The trial is an ongoing phase 2 clinical trial of ENV-105 (carotuximab) in combination with apalutamide in patients with mCRPC.
• The Current Report states the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be deemed incorporated by reference into filings under the Securities Act or the Exchange Act.

Why it may matter This report was made under Item 8.01 (other events), which covers events such as the issuance of a press release reporting interim clinical data from an ongoing trial. A filing does not show why the insider traded or why the company acted.